Allergan Sues Hi-Tech Over Pinkeye Drug Patents

Law360, New York (October 12, 2011, 8:27 PM ET) -- Allergan Inc. and two Japanese pharmaceutical companies sued Hi-Tech Pharmacal Co. Inc. in Delaware on Tuesday in a bid to stop Hi-Tech from producing a generic version of pinkeye treatment Zymaxid.

Allergan, together with Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd., claim that Hi-Tech's abbreviated new drug application submitted to the U.S. Food and Drug Administration for approval to market a version of gatifloxacin ophthalmic solution — the generic form of Zymaxid — infringes two patents.

Zymaxid is in a class of antibiotics called...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required